(RTTNews) - Savara Inc. (SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced on Friday that the U.S. Food and Drug Administration will not meet the November 22, 2026, Prescription Drug User Fee Act target action date for its Biologics
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.
